Consort Medical plc Surges After Announcing Deal With British American Tobacco plc

Consort Medical plc (LON: CSRT) has received approval for its Voke nicotine inhaler, a collaboration with British American Tobacco plc (LON: BATS).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Consort Medical (LSE: CSRT) has jumped by nearly 10% today, after the medical device company said that the Voke nicotine inhaler had received market authorisation from the UK’s Medicines and Healthcare products Regulatory Agency.

This is big news for Consort. The Voke inhaler is a device that was developed by Kind Consumer Ltd, and will be commercialised by none other than a subsidiary of global tobacco behemoth British American Tobacco (LSE: BATS).

Ready to gostock exchange

The authorisation marks an important step for British American as the company tries to develop its offering of new, safer, tobacco related products. Actually, the Voke inhaler has nothing to do with tobacco; the product is a medicinal product, delivering a precise dose of nicotine, which is designed to help smokers quit. 

The production of this device is part of British American’s drive away from traditional tobacco products. Voke represents a further move by one of the world’s big tobacco players to adapt to the rapidly changing tobacco market. 

Consort’s roll is to manufacture the Voke device, which was designed by private company Kind Consumer. Kind’s backers include former Tesco boss, Terry Leahy.

Consort is ready for immediate production and management has stated that production facilities to support the launch of the product are already in place. Additionally, the construction of facilities to support the production of full contracted volumes is well underway. 

Still, there is one more hurdle to clear. The Medicines and Healthcare products Regulatory Agency must approve a modified license of the product before full-scale production is allowed. This license is required for automated manufacture. Approvals should be in place later this year and Voke should be ready for sale during the first half of 2015.

Not an e-cigsmoking

The production of Voke really does show how big tobacco is moving away from its traditional business model. British American is suffering as a growing number of smokers kick the habit worldwide. The company’s cigarette volume sales fell 3.4% during the first half of the year.

Of course, British American’s other non-tobacco initiative is e-cigs, although the regulatory issues currently surrounding these products are worrying.

The value of the e-cig market is estimated to be worth $3.5bn per year, but competition within the sector is rife and profit margins are collapsing. British American already has an e-cig product on sale called Vype, as of yet it’s there’s little in the way of data to assess the success of the brand. 

Rising forecasts

So, how has today’s news affected Consort? Well, as covered above the market reaction has been positive and several brokers have reiterated their “buy” recommendation for the company’s shares. 

Nevertheless, Consort looks relatively expensive at current levels. The company is trading at a forward P/E of 18.9 and only offers a dividend yield of 2.2%. Earnings per share growth of 4% is expected this year, followed by 10% growth during 2016. 

Further, until the final approval is received for the Voke device, Consort’s future is uncertain. However, if British American gets the go-ahead for production, the City could quickly adjust Consort’s earnings forecasts higher. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves has no position in any shares mentioned. The Motley Fool UK owns shares in Tesco. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »